Uporaba mikofenolat mofe0la v zdravljenju SLE. Rok Ješe Klinični oddelek za revmatologijo UKC Ljubljana
|
|
- Dwayne Sparks
- 6 years ago
- Views:
Transcription
1 Uporaba mikofenolat mofe0la v zdravljenju SLE Rok Ješe Klinični oddelek za revmatologijo UKC Ljubljana
2 Mikofenolat mofe=l (MMF) 2- morfolinoe=lni ester mikofenolne kisline produkt plesni Penicillium brevicompactum Sinclair A et al. Mycophenolate mofe=l: an overview. Lupus, 2006
3 MMF mehanizem delovanja pretvorba v mikofenolno kislino (MPA) inhibicija inozin- 5- monofosfat dehidrogenaze (IMPDH) à zavora de novo sinteze gvanozinskih nukleo=dov à zavora proliferacije in ak0vacije limfocitov T in B druge celice lahko uporabijo t.i. rešilno pot (limfoci= izključno de novo) močnejša inhibicija IMPDH =p II (izražena v ak=viranih limfoci=h) ugoden vpliv na proces ateroskleroze? Sinclair A et al. Mycophenolate mofe=l: an overview. Lupus, 2006
4 MMF neželeni učinki slabost, bruhanje, diareja ( 1/10) levkopenija, anemija, trombocitopenija ( 1/10) hepa==s (1/100 1/10) okužbe teratogenost (kontraindiciran v nosečnos=) SmPC CellCept 500 mg filmsko obložene tablete
5 Natrijev mikofenolat (v gastrorezistentnih tabletah) mikofenolna kislina v obliki natrijeve soli 1000 mg MMF 720 mg Na- MPA manjša incidenca GI neželenih učinkov pantoprazol ne vpliva na farmakokine=ko Na- MPA SmPC Myfor=c 360 mg gastrorezistentne tablete Darji P et al. Conversion From Mycophenolate Mofe=l to Enteric- coated Mycophenolate Sodium in Renal Transplant Recipients With Gastrointes=nal Tract Disorders. Transplant Proc, 2008 Rupprecht K et al. Bioavailability of Mycophenolate Mofe=l and Enteric- Coated Mycophenolate Sodium Is Differen=ally Affected by Pantoprazole in Healthy Volunteers. J Clin Pharmacol, 2013
6 MMF in SLE zgodovina 1995: pričetek uporabe (preprečevanje zavrnitve po presaditvi ledvice) 1998: prva uporaba za SLE (refraktarni lupusni glomerulonefri=s) 1999: prva serija primerov SLE (rezistentni in relapsirajoči prolifera=vni LGN) 2000: prva randomizirana kontrolirana raziskava za SLE (difuzni prolifera=vni LGN) Sinclair A et al. Mycophenolate mofe=l: an overview. Lupus, 2006
7 MMF in lupusni glomerulonefri=s (indukcijsko zdravljenje) 2 ključni raziskavi: Ginzler et al., 2005 [N=140, 24 tednov] Appel et al. (ALMS Group), 2009 [N=370, 24 tednov] LGN razred III, IV ali V MMF [1 à 3 g/dan] vs. IV CYC 6x[0,5 à 1 g/m 2 /mesec]
8 Indukcijsko zdravljenje LGN Ginzler EM et al. Mycophenolate Mofe=l or Intavenous Cyclophosphamide for Lupus Nephri=s. N Engl J Med, 2005
9 Indukcijsko zdravljenje LGN Appel GB et al. Mycophenolate Mofe=l versus Cyclophosphamie for Induc=on Treatment of Lupus Nephri=s. J Am Soc Nephrol, 2009
10 Indukcijsko zdravljenje LGN prolifera0vni LGN (III, IV): MMF (3g/dan) pri večini primerov (1A) IV CYC po Euro- Lupus shemi pri belcih (1B) IV CYC po NIH shemi primerljivo učinkovit, bolj toksičen (vendar edini dokazano učinkovit pri neugodnih prognos=čnih znakih) učinkovitost MMF verjetno večja pri temnopol=h membranski LGN (V): MMF pri večini primerov (2B) IV CYC po NIH shemi primerljivo učinkovit, bolj toksičen Bertsias GK et al. Joint European League Against Rheuma=sm and European Renal Associa=on European Dialysis and Transplant Associa=on (EULAR/ERA- EDTA) recommenda=ons for the management of adult and paediatric lupus nephri=s. Ann Rheum Dis, 2012
11 MMF in lupusni glomerulonefri=s (vzdrževalno zdravljenje) 2 ključni raziskavi: Houssiau et al. (MAINTAIN Trial), 2010 [N=105, 48 mesecev] (po indukciji z MP 3x750 mg + IV CYC 6x[500 mg/2 tedna]) Dooley et al. (ALMS Group), 2011 [N=227, 36 mesecev] (po indukciji z MMF ali IV CYC 6x[0,5 à 1 g/m 2 /mesec]) MMF [2 g/dan] vs. AZA [2 mg/kg/dan]
12 Vzdrževalno zdravljenje LGN Houssiau FA et al. Azathioprine versus Mycophenolate Mofe=l for Long- term immunosuppression in Lupus Nephri=s: Resilts from the MAINTAIN Nephri=s Trial. Ann Rheum Dis, 2010
13 Vzdrževalno zdravljenje LGN Dooley MA et al. Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephri=s. N Engl J Med, 2011
14 Vzdrževalno zdravljenje LGN MMF ali AZA - primerljiva učinkovitost (1A) nadaljevanje z MMF ob uspešnem indukcijskem zdravljenju Aza=oprin (AZA) v primeru načrtovane nosečnos= Kalcinevrinski inhibitorji (CNI) v izbranih primerih Bertsias GK et al. Joint European League Against Rheuma=sm and European Renal Associa=on European Dialysis and Transplant Associa=on (EULAR/ERA- EDTA) recommenda=ons for the management of adult and paediatric lupus nephri=s. Ann Rheum Dis, 2012
15 MMF in lupusni glomerulonefri=s Priporočila EULAR/ERA- EDTA (2012): Bertsias GK et al. Joint European League Against Rheuma=sm and European Renal Associa=on European Dialysis and Transplant Associa=on (EULAR/ERA- EDTA) recommenda=ons for the management of adult and paediatric lupus nephri=s. Ann Rheum Dis, 2012
16 MMF in zunajledvične manifestacije SLE ni (ločenih) podatkov o učinkovitos= iz randomiziranih študij posamezni primeri uspešnega zdravljenja rezistentnih manifestacij SLE: huda trombocitopenija, hemoli=čna anemija difuzna alveolarna krvavitev, kronični inters=cijski pnevmoni=s nevropsihiatrični SLE artri=s, kožni LE (ne CCLE?) enteri=s MMF predstavlja alterna0vo (Aringer et al., 2013): če z uveljavljenimi imunosupresivi ni mogoče umiri= bolezni če ni mogoče znižanje odmerka glukokor=koidov do 7,5 mg prednizolona/dan Doria A et al. Mycophenolate Mofe=l and Systemic Lupus Erythematosus. Lupus, 2006 Aringer M et al. Stellungnahme zum Einsatz von Mycophenolat- Mofe=l beim systemischen Lupus erythematodes. Z Rheumatol, 2013
17 MMF in zunajledvične manifestacije SLE Ginzler et al. (ALMS Group), 2009 (ak=vnost bolezni po BILAG indeksu ob indukcijskem zdravljenju LGN) Ginzler EM et al. Nonrenal Disease Ac=vity Following Mycophenolate Mofe=l or Intravenous Cyclophosphamide as Induc=on Treatment for Lupus Nephri=s. ArthriBs Rheum, 2010
18 Uporaba MMF na KOR UKCLJ (hospitalizirani pacien= s SLE 1/ /2014) Vsi hospitalizirani pacien0, N=66 Zadnja vzdrževalna terapija Pacien0 s prvič ugotavljano ledvično prizadetostjo, N=20 Zadnja vzdrževalna terapija MMF AZA CNI MTX MP+CQ CQ MP MMF AZA CNI MP+CQ RTX RTX
19 Zaključek MMF pri zdravljenju lupusnega glomerulonefri0sa: indukcija: primerljiva učinkovitost s CYC, manjša toksičnost vzdrževanje: primerljiva (boljša?) učinkovitost kot AZA à Zdravilo prve izbire za večino pacientov s prolifera0vnim in/ ali membranskim LGN Alterna=vno zdravilo za rezistentne zunajledvične manifestacije SLE MMF s pridom uporabljamo tudi na KOR UKCLJ
20
Switching Treatment Between Mycophenolate Mofetil and Azathioprine in Lupus Patients: Indications and Outcomes
Arthritis Care & Research Vol. 66, No. 12, December 2014, pp 1905 1909 DOI 10.1002/acr.22364 2014, American College of Rheumatology ORIGINAL ARTICLE Switching Treatment Between Mycophenolate Mofetil and
More informationLupus and Your Kidneys. Michael P. Madaio, MD Professor of Medicine Chairman of Medicine Medical College of Georgia Augusta, Georgia
Lupus and Your Kidneys Michael P. Madaio, MD Professor of Medicine Chairman of Medicine Medical College of Georgia Augusta, Georgia Kidney Inflammation and Abnormal Function as a Result of Lupus (Lupus
More informationLupus Related Kidney Diseases. Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017
Lupus Related Kidney Diseases Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017 Financial Disclosures MedImmune Lupus Nephritis Kidney Biopsy Biomarkers
More informationLupus Nephritis New (?) Treatments. Aurélie HUMMEL Service de Néphrologie Hôpital Necker Enfants-Malades Paris
Lupus Nephritis New (?) Treatments Aurélie HUMMEL Service de Néphrologie Hôpital Necker Enfants-Malades Paris Introduction Lupus nephritis : 30-50% of patients with lupus = mortality risk factor Mok Series
More informationEffect of mycophenolate mofetil on the white blood cell count and the frequency of infection in systemic lupus erythematosus.
Thomas Jefferson University Jefferson Digital Commons Department of Medicine Faculty Papers Department of Medicine 10-22-2015 Effect of mycophenolate mofetil on the white blood cell count and the frequency
More informationRecent advances in management of Pulmonary Vasculitis. Dr Nita MB
Recent advances in management of Pulmonary Vasculitis Dr Nita MB 23-01-2015 Overview of the seminar Recent classification of Vasculitis What is new in present classification? Trials on remission induction
More informationProton Pump Inhibitors do not Interact with the Immunosuppressant Enteric-Coated Mycophenolate Sodium
Proton Pump Inhibitors do not Interact with the Immunosuppressant Enteric-Coated Mycophenolate Sodium S. Kofler, C. Wolf, Z. Sisic, J. Behr, M. Vogeser, M. Shipkova, B. Meiser, G. Steinbeck, B. Reichart,
More informationLupus nephritis. Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic
Lupus nephritis Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic Disclosure of Interests Abbvie, Amgen, Baxter, Bayer, Boehringer-Ingelheim, Calliditas, Chemocentryx,
More informationIRACON Management of Lupus Nephritis: Old is gold, New is Trendy
IRACON 2016 Management of Lupus Nephritis: Old is gold, New is Trendy First episode of LN (III/IV): Induction Low dose is equally considerable as high dose CYC Switch to the other agent if no improvement
More informationSevere lupus nephritis: the predictive value of a 50% reduction in proteinuria at 6 months
Nephrol Dial Transplant (2013) 28: 2313 2318 doi: 10.1093/ndt/gft201 Advance Access publication 19 June 2013 Severe lupus nephritis: the predictive value of a 50% reduction in proteinuria at 6 months Stephen
More informationIdentification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome
To cite: Dall Era M, Levesque V, Solomons N, et al. Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Lupus Science
More informationANCA+ VASCULITIDES CYCAZAREM,
ANCA+ VASCULITIDES CYCAZAREM, q Comparison of 3 to 6 mo. oral CYC + CS then azathioprine or oral CYC for 12 mo.+ 10 mg/d CS. After 12 mo all the patients were treated with azathioprine q 150 patients followed
More informationOutcome of low dose cyclophosphamide for induction phase treatment of lupus nephritis, a single center study
Sigdel et al. BMC Nephrology (2016) 17:145 DOI 10.1186/s12882-016-0361-0 RESEARCH ARTICLE Open Access Outcome of low dose cyclophosphamide for induction phase treatment of lupus nephritis, a single center
More informationREMISSION OF ACTIVE LUPUS NEPHRITIS WITH VOCLOSPORIN: RESULTS OF THE AURA-LV STUDY
REMISSION OF ACTIVE LUPUS NEPHRITIS WITH VOCLOSPORIN: RESULTS OF THE AURA-LV STUDY V. Dobronravov* 1, M. A. Dooley 2, S. A. Haq 3, I. Adzerikho 4, O. Bugrova 5, D. Isenberg 6, F. Houssiau 7, N. Solomons
More informationKidney disease associated with autoimmune disease
Kidney disease associated with autoimmune disease Masaomi Nangaku Division of Nephrology and Endocrinology the University of Tokyo Graduate School of Medicine, Japan M-type Phospholipase A2 Receptor as
More informationSYSTEMIC LUPUS ERYTHEMATOSUS: CURRENT CONCEPTS AND CLINICAL PEARLS. Dr Sheila Vasoo Consultant Division of Rheumatology NUHS
SYSTEMIC LUPUS ERYTHEMATOSUS: CURRENT CONCEPTS AND CLINICAL PEARLS Dr Sheila Vasoo Consultant Division of Rheumatology NUHS Listen to the Patient Concepts Diagnosis Immunopathogenesis Clinical Pearls Disease
More informationIntruduction PSI MODE OF ACTION AND PHARMACOKINETICS
Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation Andreas Zuckermann, MD et al. Department of Cardio-Thoracic Surgery, Medical University
More informationTaming the wolf: Treating to target, treating to remission new strategies for SLE
Taming the wolf: Treating to target, treating to remission new strategies for SLE Ronald van Vollenhoven Seattle, April 28, 2017 Disclosures Research support, consultancy: Abbott (AbbVie), Biotest, BMS,
More informationManagement and Prognosis of Lupus Nephritis
Management and Prognosis of Lupus Nephritis Dimitrios T Boumpas National and Kapodistrian University of Athens Special thanks to G Bertsias, University of Crete Key Questions in Lupus Nephritis Is it common?
More informationAntikoagulantno zdravljenje
Antikoagulantno zdravljenje (novosti s kongresa ASH 2010) Irena Umek Bricman Oddelek za interno medicino SB Slovenj Gradec Podčetrtek, 15.04.2010 Trajanje antikoagulantne terapije Priporočila: 8th ACCP
More informationLONG-TERM OUTCOME OF PATIENTS WITH LUPUS NEPHRITIS: A SINGLE CENTER EXPERIENCE
& LONG-TERM OUTCOME OF PATIENTS WITH LUPUS NEPHRITIS: A SINGLE CENTER EXPERIENCE Senija Rašić 1 *, Amira Srna 1, Snežana Unčanin 1, Jasminka Džemidžić 1, Damir Rebić 1, Alma Muslimović 1, Maida Rakanović-Todić
More informationREPEATED B CELL DEPLETION IN TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
ARD Online First, published on November 3, 2005 as 10.1136/ard.2005.044487 REPEATED B CELL DEPLETION IN TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS Concise report Kristine P. Ng 1 Maria J. Leandro
More informationZdravljenje pridobljene hemofilije. Irena Preložnik Zupan
Zdravljenje pridobljene hemofilije Irena Preložnik Zupan CILJI 1. Definicija, klinična slika, diagnoza 2. Zdravljenje zdravljenje akutnih krvavitev odstranjevanje inhibitorjev Pridobljeni inhibitorji koagulacije
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Wed, 20 Jun 2018 01:15:28 GMT) CTRI Number Last Modified On 29/12/2012 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationRéférence bibliographique. "Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis"
"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis" Dooley, Mary Anne ; Jayne, David ; Ginzler, Ellen M ; Isenberg, David ; Olsen, Nancy J ; Wofsy, David ; Eitner, Frank ; Appel,
More informationSystemerkrankungen mit Nierenbeteiligung
Systemerkrankungen mit Nierenbeteiligung ÖGN Fuschl 2012 Irmgard Neumann Wilhelminenspital Wien Induktions-Therapie Generalisiert CYC i.v. pulse = CYC oral CYCLOPS, de Groot, Ann Int Med 2009 RIT vs CYC
More informationALI JE DOLGOTRAJNA UPORABA ZAVIRALCEV PROTONSKE ČRPALKE VARNA?
ALI JE DOLGOTRAJNA UPORABA ZAVIRALCEV PROTONSKE ČRPALKE VARNA? Darja Logar, dr. med. Barbara Mazej Poredoš, dr. med. Ljubljana, 18. 10. 2012 Dandanes se izjemno povečuje poraba ZPČ, čemur smo priča tudi
More informationRandom pharmacokinetic profiles of EC-MPS in children with autoimmune disease
RESEARCH Open Access Random pharmacokinetic profiles of EC-MPS in children with autoimmune disease Guido Filler *, Ajay Parkash Sharma, Deborah M Levy, Abeer Yasin Abstract Background: Therapy with mycophenolate
More informationTransplantation in Australia and New Zealand
Transplantation in Australia and New Zealand Matthew D. Jose MBBS (Adel), FRACP, FASN, PhD (Monash), AFRACMA Professor of Medicine, UTAS Renal Physician, Royal Hobart Hospital Overview CKD in Australia
More information29/10. Treatment (brand name, manufacturer): For the treatment of: Background: Rituximab (MabThera, Roche) SLE in adults (unlicensed)
GENERAL POLICY Policy Ref: 29/10 Treatment (brand name, manufacturer): For the treatment of: Background: Commissioning position: Rituximab (MabThera, Roche) SLE in adults (unlicensed) There are frequent
More informationPriporočila za zdravljenje primarne imunske trombocitopenije. Barbara Skopec
Priporočila za zdravljenje primarne imunske trombocitopenije Barbara Skopec ITP = Idiopatična trombocitopenična purpura ITP = primarna imunska trombocitopenija Rodeghiero F, et al. Blood 2009;113:2386
More informationIntravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis
Int Urol Nephrol (2013) 45:1301 1308 DOI 10.1007/s11255-012-0331-9 NEPHROLOGY - ORIGINAL PAPER Intravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis Prayong Vachvanichsanong
More information47 studies found for: systemic lupus erythematosus AND mycophenolic acid
Recherche in auf der Webseite www.clinicaltrials.gov zuletzt am 16.02.2016 47 studies found for: systemic lupus erythematosus AND mycophenolic acid Rank Status Study 1 Terminate d Myfortic Versus Azathioprine
More informationLong-term follow-up in lupus nephritis patients treated with rituximab clinical and histopathological response
RHEUMATOLOGY Rheumatology 2013;52:847 855 doi:10.1093/rheumatology/kes348 Advance Access publication 3 January 2013 Original article Long-term follow-up in lupus nephritis patients treated with rituximab
More informationGINKGO BILOBA IN MISELNE SPOSOBNOSTI. Avtorji: Jelena Raković, Božica Ljušanin Grbavac 18. modularna skupina April 2015
GINKGO BILOBA IN MISELNE SPOSOBNOSTI Avtorji: Jelena Raković, Božica Ljušanin Grbavac 18. modularna skupina April 2015 KLINIČNO VPRAŠANJE Ali uporaba standardiziranih pripravkov Ginkgo bilobe izboljšuje
More informationAdditional file 2: Details of cohort studies and randomised trials
Reference Randomised trials Ye et al. 2001 Abstract 274 R=1 WD=0 Design, numbers, treatments, duration Randomised open comparison of: (45 patients) 1.5 g for 3, 1 g for 3, then 0.5 to 0.75 g IV cyclophosphamide
More informationMycophenolate Mofetil for Induction Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis
Mycophenolate Mofetil for Induction Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis Michael Walsh,* Matthew James,* David Jayne, Marcello Tonelli, Braden J. Manns,* and Brenda R. Hemmelgarn*
More informationIn the United States, induction therapy for the treatment of
Oral Cyclophosphamide for Lupus Glomerulonephritis: An Underused Therapeutic Option Alison McKinley,* Edward Park,* Dan Spetie,* Kevin V. Hackshaw, Smitha Nagaraja,* Lee A. Hebert,* and Brad H. Rovin*
More informationLONGITUDINAL TREATMENT PATTERNS AND ASSOCIATED OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED SYSTEMIC LUPUS ERYTHEMATOSUS. Hong Kan 7/12/2016
LONGITUDINAL TREATMENT PATTERNS AND ASSOCIATED OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED SYSTEMIC LUPUS ERYTHEMATOSUS Hong Kan 7/12/2016 1 Acknowledgements Research conceptualization and design, programming
More informationRussia Dialysis Society Peterhof, Russia June 8, 2016
Russia Dialysis Society Peterhof, Russia June 8, 2016 TREATMENT OF GLOMERULONEPHRITIS XV Северо-Западная ( AAV, SLE, Нефрологическая Membranous) Школа What s changed in the past decade? William Couser,
More informationEULAR/ERA-EDTA recommendations for the management of ANCAassociated
EULAR/ERA-EDTA recommendations for the management of ANCAassociated vasculitis Dr. Meharunnisha Syed III year DNB Resident (General Medicine) Narayana Health-MSH Fifteen recommendations were developed,
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/47854 holds various files of this Leiden University dissertation Author: Wilhelmus, S. Title: Systemic lupus erythematosus: pathogenesis, diagnosis, and
More informationNierenbeteiligung bei Systemerkrankungen
Nierenbeteiligung bei Systemerkrankungen ÖGN 2018 Irmgard Neumann www.vasculi*s.at Avacopan (CCX168) Small molecule, orally administered Highly selecgve C5aR inhibitor Prevented MPO- ANCA mediated GlomerulonephriGs
More informationUnderstanding Myositis Medications
Understanding Myositis Medications 2015 TMA Annual Patient Conference Orlando, Florida Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Disclosures Mallinckrodt: Research Grant Genentech:
More informationTreatment for lupus is evolving. This review summarizes
172 Treatment of Systemic Lupus Erythematosus A 2012 Update Joan T. Merrill, M.D. Treatment for lupus is evolving. This review summarizes some of the major recommendations for care from the time of the
More informationHorizon Scanning Centre May Tabalumab for systemic lupus erythematosus SUMMARY NIHR HSC ID: 5581
Horizon Scanning Centre May 2014 Tabalumab for systemic lupus erythematosus SUMMARY NIHR HSC ID: 5581 This briefing is based on information available at the time of research and a limited literature search.
More informationRandomized trial of enteric-coated mycophenolate sodium versus mycophenolate mofetil in multi-system autoimmune disease
Clin Kidney J (2014) 7: 562 568 doi: 10.1093/ckj/sfu096 Advance Access publication 16 September 2014 Clinical Research Randomized trial of enteric-coated mycophenolate sodium versus mycophenolate mofetil
More informationCommentary on KDIGO glomerulonephritis guidelines Richard Coward, Megan Griffith and Michael Robson
Commentary on KDIGO glomerulonephritis guidelines Richard Coward, Megan Griffith and Michael Robson Introduction This report comments on the likely relevance and utility of the recently published global
More informationASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/381922/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER The Paediatric Working Party
More informationLupus nephritis management guidelines compared
Nephrol Dial Transplant (2016) 31: 904 913 doi: 10.1093/ndt/gfv102 Advance Access publication 28 April 2015 Lupus nephritis management guidelines compared Suzanne Wilhelmus 1, Ingeborg M. Bajema 1, George
More informationTREATMENT OF ANCA-ASSOCIATED VASCULITIS
TREATMENT OF ANCA-ASSOCIATED VASCULITIS Loïc Guillevin Hôpital Cochin, Université Paris Descartes Cours DU, 11 mars 2016 1 Disclosure of interest regarding this presentation Roche has provided, in part,
More informationANCA associated vasculitis in China
ANCA associated vasculitis in China Min Chen Renal Division, Peking University First Hospital, Beijing 100034, P. R. China 1 General introduction of AAV in China Disease spectrum and ANCA type Clinical
More informationMesto mikofenolata v nefrologiji
MED RAZGL 2006; 45: 301 306 PREGLEDNI ^LANEK Andrej Bren 1, Aljo{a Kandus 2 Mesto mikofenolata v nefrologiji Place of Mycophenolate in Nephrology IZVLE^EK KLJU^NE BESEDE: mikofenolat, nefrologija V ~lanku
More informationAURION STUDY: 48-WEEK DATA OF MULTI-TARGET THERAPY WITH VOCLOSPORIN, MMF AND STEROIDS FOR ACTIVE LUPUS NEPHRITIS
AURION STUDY: 48-WEEK DATA OF MULTI-TARGET THERAPY WITH VOCLOSPORIN, MMF AND STEROIDS FOR ACTIVE LUPUS NEPHRITIS The 12th International Congress on Systemic Lupus Erythematosus (LUPUS 2017) & the 7th Asian
More informationIf It s Not One Thing It s Another: Transformation of Lupus Nephritis
HALLWAY CONSULT If It s Not One Thing It s Another: Transformation of Lupus Nephritis By Julie Barsalou, MD, FRCPC; Rohan John, MD; and Joanne M. Bargman, MD, FRCPC A 25-year-old Haitian-born woman presents
More informationEfficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis
ARTHRITIS & RHEUMATISM Vol. 65, No. 9, September 2013, pp 2368 2379 DOI 10.1002/art.38037 2013, American College of Rheumatology Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis
More informationONE of the following:
Medical Coverage Policy Belimumab (Benlysta) EFFECTIVE DATE: 01 01 2012 POLICY LAST UPDATED: 11 21 2017 OVERVIEW Belimumab (Benlysta ) is indicated for the treatment of adult patients with active, autoantibody-positive,
More informationSMALL TO MEDIUM VASCULITIS: RENAL ASPECT RATANA CHAWANASUNTORAPOJ UPDATE IN INTERNAL MEDICINE 2018
SMALL TO MEDIUM VASCULITIS: RENAL ASPECT RATANA CHAWANASUNTORAPOJ UPDATE IN INTERNAL MEDICINE 2018 OUTLINE Renal involvement in vasculitis Curr Rheumatol Rep 2013 Renal involvement in ANCA vasculitis GN***:
More informationReviewer No. 2 checklist for: DMARDS Review for children. In the WHO Essential Medicines List
Reviewer No. 2 checklist for: DMARDS Review for children In the WHO Essential Medicines List (1) Have all important studies that you are aware of been included? (2) Is there adequate evidence of efficacy
More informationRenal Flare as a Predictor of Incident and Progressive CKD in Patients with Lupus Nephritis
Article Renal Flare as a Predictor of Incident and Progressive in Patients with Lupus Nephritis Samir V. Parikh,* Haikady N. Nagaraja, Lee Hebert,* and Brad H. Rovin* Summary Background and objectives
More informationMycophenolate mofetil in the treatment of lupus nephritis
REVIEW Mycophenolate mofetil in the treatment of lupus nephritis Patrick FK Yong 1,2 David P D Cruz 2 1 Department of Clinical Immunology, Kings College Hospital; 2 The Lupus Research Unit, St Thomas Hospital,
More informationTriple Drug Regimen as Induction Treatment of Lupus Nephritis: a Pilot Randomized Controlled Trial -
International Journal of Nephrology & Therapeutics Research Article Triple Drug Regimen as Induction Treatment of Lupus Nephritis: a Pilot Randomized Controlled Trial - Arpita Roy Chowdhury*, Subho Banerjee,
More informationCHAPTER 4 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND PROLIFERATIVE LUPUS NEPHRITIS. Gabriëlle M.N.
CHAPTER 4 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND PROLIFERATIVE LUPUS NEPHRITIS Gabriëlle M.N. Daleboudt Stefan P. Berger Ad A. Kaptein Psychology, Health, & Medicine
More informationConsidering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol
Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol Patient details Name DOB ESRD Other history Mr. B.I.B. 12 January 1975 (34yo) Membranous GN
More informationENFERMEDADES AUTOINMUNES SISTÉMICAS. Dr. José María Pego Reigosa
ENFERMEDADES AUTOINMUNES SISTÉMICAS Dr. José María Pego Reigosa ABSTRACT NUMBER: 2754 Comparison of Individually Tailored vs Systematic Rituximab Regimens to Maintain ANCA-Associated Vasculitis Remissions:
More informationEfficacy and safety of mycophenolate mofetil and tacrolimus combination therapy in patients with lupus nephritis: a nationwide multicentre study
Efficacy and safety of mycophenolate mofetil and tacrolimus combination therapy in patients with lupus nephritis: a nationwide multicentre study D.-J. Park 1, J.-H. Kang 1, K.-E. Lee 1, S.-C. Bae 2, W.-T.
More informationSladkorna bolezen in kirurški poseg
Sladkorna bolezen in kirurški poseg Doc.dr.Vilma Urbančič, dr.med. UKC Ljubljana KO EDBP, Diabetološki oddelek 1.12.2010 10. Podiplomski tečaj iz hospitalne diabetologije Ljubljana, 24.11. -2.12.2010 Noordzij
More informationDiagnostika in zdravljenje SLE. Matija Tomšič KO za revmatologijo UKC Ljubljana
Diagnostika in zdravljenje SLE Matija Tomšič KO za revmatologijo UKC Ljubljana M.H., rojena 1977 1993 zbolela v starosti 16 let: metuljast eritem obraza, levkopenija, proteinurija, patološki sediment seča
More informationProphylaxis of acute transplant rejection in patients receiving allogeneic renal transplants:
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Prophylaxis of acute transplant rejection in patients receiving allogeneic renal transplants: Over 1 million people worldwide
More informationNew Developments in ANCA-associated Vasculitis
New Developments in ANCA-associated Vasculitis Second International Renal Conference Bruges, March 2018 Ulrich Specks, M.D. Connor Group Foundation Professor of Medicine Mayo Clinic College of Medicine
More informationALI SO PRIPRAVKI GLUKOZAMINA UČINKOVITI V TERAPIJI GONARTROZE?
ALI SO PRIPRAVKI GLUKOZAMINA UČINKOVITI V TERAPIJI GONARTROZE? SPECIALIZACIJA IZ DRUŽINSKE MEDICINE MODUL: NA DOKAZIH TEMELJEČA MEDICINA 16. SKUPINA AVTORJI: MIRJANA NINKOV MILA MRŠIĆ OLIVER ILIĆ OPIS
More informationCorrespondence should be addressed to A. Oglesby;
International Journal of Rheumatology Volume 2013, Article ID 347520, 9 pages http://dx.doi.org/10.1155/2013/347520 Review Article Adverse Event Burden, Resource Use, and Costs Associated with Immunosuppressant
More informationPost-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies
Post-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies Lorita M Rebellato, Ph.D., D (ABHI) Associate Professor Department of Pathology The Brody School of Medicine at ECU Scientific
More informationLong-term Outcome of Diffuse Proliferative Lupus Glomerulonephritis Treated with Cyclophosphamide
The American Journal of Medicine (2006) 119, 355.e25-355.e33 CLINICAL RESEARCH STUDY Long-term Outcome of Diffuse Proliferative Lupus Glomerulonephritis Treated with Cyclophosphamide Chi Chiu Mok, MD,
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Update on Granulomatosis with Polyangiitis (Wegener s) Learning Objectives Identify the clinical features of granulomatosis with
More informationComparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial
(2017) 0, 1 10 journals.sagepub.com/home/lup PAPER Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial N Kamanamool 1,2, A Ingsathit
More informationBK Virus (BKV) Management Guideline: July 2017
BK Virus (BKV) Management Guideline: July 2017 BK virus has up to a 60-80% seroprevalence rate in adults due to a primary oral or respiratory exposure in childhood. In the immumocompromised renal transplant
More informationPediatric Pharmacotherapy
Pediatric Pharmacotherapy A Monthly Review for Health Care Professionals of the Children's Medical Center Volume 4 Number 8, August 1998 Mycophenolate mofetil: Use in pediatrics Beth Ann Fullmer, R.Ph.,
More informationANCA-associated vasculitis. Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic
ANCA-associated vasculitis Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic Disclosure of Interests Abbvie, Amgen, Baxter, Bayer, Boehringer-Ingelheim, Calliditas,
More informationZdravila s farmakološkim učinkom na srcu
Zdravila s farmakološkim učinkom na srcu Prof. dr. Mojca Kržan Inštitut za farmakologijo in eksperimentalno toksikologijo, Medicinska fakulteta, Univerza v Ljubljani Zdravila s farmakološkim učinkom na
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationDepartment of Pediatrics, Division of Rheumatology, Children s Hospital at Montefiore, Bronx, New York, 10467, USA
REVIEW Proliferative nephritis in childhood-onset systemic lupus erythematosus: current therapeutic approaches and future perspectives [version 1; referees: 1 approved, 1 approved with reservations] Dawn
More informationSystemic Lupus Erythematosus
Systemic Lupus Erythematosus Translating Pathophysiology into New Therapies Traduciendo fisiopatologia en nuevos tratamentos Asociacion Costarricense Medicina Interna August 7, 2015 Arthur Weinstein, MD,
More informationTell me more about vasculitis. Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital
Tell me more about vasculitis Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital Talk overview Case study ANCA-associated vasculitis What is ANCA vasculitis? What causes ANCA
More informationLupus The Clinical Perspective
Lupus The Clinical Perspective Anca D. Askanase, M.D., M.P.H. Associate Professor of Medicine Director Lupus Center Columbia University Medical Center New York-Presbyterian Hospital Systemic Lupus Erythematosus
More informationBeyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis
Nephrol Dial Transplant (2013) 28: 106 111 doi: 10.1093/ndt/gfs285 Advance Access publication 3 July 2012 Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis Marc Weidenbusch, Christoph
More informationEfficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional
http://informahealthcare.com/mor ISSN 1439-7595 (print), 1439-7609 (online) Mod Rheumatol, 2016; 26(1): 80 86 2015 Japan College of Rheumatology. Published by Taylor & Francis. DOI: 10.3109/14397595.2015.1060665
More informationMohanram Narayanan MD, FACP, FASN, FNKF,FRCP (C) Reference List Abstract
Abstract Primary Hyperoxaluria Causing ESRD and Lower Extremity Gangrene 662 Nidhi Munshi, Mohanram Narayanan 66E Abstract and Poster presented at the Annual Dialysis Conference March, Orlando, FL. 2008
More informationCooper et al. Pediatric Rheumatology (2018) 16:65 (Continued on next page)
Cooper et al. Pediatric Rheumatology (2018) 16:65 https://doi.org/10.1186/s12969-018-0279-0 RESEARCH ARTICLE Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment
More informationBelimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review
Margiotta et al. BMC Nephrology (2018) 19:54 https://doi.org/10.1186/s12882-018-0847-z CASE REPORT Open Access Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis:
More informationOBJECTIVES. Phases of Transplantation and Immunosuppression
Transplant and Immunosuppression: Texas Transplant Center April 29, 2017 Regina L. Ramirez, Pharm.D., BCPS PGY1 Pharmacy Residency Program Director Clinical Practice Specialist Solid Organ Transplant and
More informationBenlysta. Benlysta (belimumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.99.01 Subject: Benlysta Page: 1 of 5 Last Review Date: June 22, 2018 Benlysta Description Benlysta (belimumab)
More informationRheumatology Advance Access published March 7, Induction treatment of ANCA-associated vasculitis with a single dose of rituximab
Original article Rheumatology Advance Access published March 7, 2014 RHEUMATOLOGY 262 doi:10.1093/rheumatology/ket489 Induction treatment of ANCA-associated vasculitis with a single dose of rituximab Tabitha
More informationRenal transplantation
NEPHROLOGY 2008; 13, S37 S43 doi:10.1111/j.1440-1797.2008.00996.x Renal transplantation Date written: November 2006 Final submission: July 2007 Author: Nigel Toussaint GUIDELINES No recommendations possible
More informationBMC Research Notes. Open Access CASE REPORT
https://doi.org/10.1186/s13104-018-3271-3 BMC Research Notes CASE REPORT Open Access Fatal visceral disseminated varicella zoster infection during initial remission induction therapy in a patient with
More information2017 CST-Astellas Canadian Transplant Fellows Symposium. Management of Renal Dysfunction in Extra Renal Transplants
2017 CST-Astellas Canadian Transplant Fellows Symposium Management of Renal Dysfunction in Extra Renal Transplants Jeffrey Schiff, MD Dr. Jeffrey Schiff is an Assistant Professor of Medicine at the University
More informationREACH Risk Evaluation to Achieve Cardiovascular Health
Dyslipidemia and transplantation History: An 8-year-old boy presented with generalized edema and hypertension. A renal biopsy confirmed a diagnosis of focal segmental glomerulosclerosis (FSGS). After his
More informationLupus Nephritis: Maintenance Therapy for Lupus Nephritis Do We Now Have a Plan?
Lupus Nephritis: Maintenance Therapy for Lupus Nephritis Do We Now Have a Plan? Oliver Lenz,* Ahmed A. Waheed, Abdur Baig, Alexander Pop, and Gabriel Contreras* Summary Lupus nephritis (LN) increases the
More informationVascularites rénales associées aux ANCA
Vascularites rénales associées aux ANCA Société Médicale des Hôpitaux de Paris 16 Mars 2012 Philippe Vanhille Néphrologie et Médecine Interne Hôpital de Valenciennes Classification of systemic vasculitis:
More informationWhat is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham
What is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham SYMPHONY Study Ekberg et al. NEJM 2008 Excluded: DCD kidneys; CIT>30hours;
More information